Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jerry Olson who wrote (90016)	3/26/2000 2:57:00 PM
From: johnsto1	Read Replies (1) \| Respond to of 120523

TGEN Targeted Genetics Corp. rose 7/8, or 7 percent, to 13 3/8. The company that researches gene therapy was rated 'buy' in new coverage by Jay Kim at Chase H&Q. 'There are multiple players in gene therapy, and clearly I think their position is one of the best.' Kim said. 'They've done some really good work.' Kim expects Targeted will have positive announcements in May on a gene therapy treatment for head, neck and ovarian cancer. In June, the company should have encouraging news about a treatment for cystic fibrosis, Kim said. entire article can be found at: cnetinvestor.com